ArticleJournal of global oncology2016
Open access · goldAbstract read
In one paragraph
Article in Journal of global oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer.Cancers · 2026Review
- Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC.NPJ precision oncology · 2026Article
- Spectrum of rareNarra J · 2025Observational
- Genetic Ancestry and Lung Cancer in Latin American Patients: A Crucial Step for Understanding a Diverse Population.Clinical lung cancer · 2025Review
- Lung Cancer Clinical Trials in Latin America in the Era of Cooperative Groups: A 20-Year Analysis.JCO global oncology · 2024Article
- Genomic landscape and tumor mutational features of resected preinvasive to invasive lung adenocarcinoma.Frontiers in oncology · 2024Article
- Practice-Level Variation in Molecular Testing and Use of Targeted Therapy for Patients With Non-Small Cell Lung Cancer and Colorectal Cancer.JAMA network open · 2023Article
- Cancer Epidemiology in Hispanic Populations: What Have We Learned and Where Do We Need to Make Progress?Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Review
- Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico.Cancers · 2020Article
- STRA6 Polymorphisms Are Associated With EGFR Mutations in Locally-Advanced and Metastatic Non-Small Cell Lung Cancer Patients.Frontiers in oncology · 2020Article
- Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study.World journal of oncology · 2019Article
- Prevalence of EGFR Mutations and Clinico-Pathological Characteristics of Chilean Lung Cancer PatientsAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017Article
- High Epidermal Growth Factor Receptor Mutation Rates in Peruvian Patients With Non-Small-Cell Lung Cancer: Is It a Matter of Asian Ancestry?Journal of global oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Ariel Lopez-Chavez, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Anish Thomas, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Moses O Evbuomwan, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Liqiang Xi, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Guinevere Chun, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Tatiana Vidaurre, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Oscar Arrieta, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
George Oblitas, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Ana Belen Oton, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Alejandro R Calvo, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Arun Rajan, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Mark Raffeld, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Seth M Steinberg, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Lorena Arze-Aimaretti, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
Giuseppe Giaccone, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; , , , , , , , and , Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; , Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; , Instituto Nacional de Cancerologia, Mexico City, Mexico; , Hospital Oncologico Luis Razetti, Caracas, Venezuela; , Denver Health Medical Center, University of Colorado, Denver, CO; , Kettering Cancer and Blood Specialists, Kettering, OH; and , Facultad de Medicina de la Universidad del Valle, Cochabamba, Bolivia.
National Cancer Institute · US
Funding
Molecular Diagnostics Core LaboratoryZICBC011079 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI XI, LIQIANG · 2009 to 2025
$33.8MAbstract
purposeEpidermal growth factor receptor ( PATIENTS AND
methodsSamples from 642 patients with NSCLC from seven institutions in the United States and Latin America were assessed for
results
conclusionThere was no significant difference between the frequency of
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.